Race, genetic ancestry and response to antidepressant treatment for major depression

Neuropsychopharmacology

Volumn 38, Issue 13, 2013, Pages 2598-2606

  Murphy, Eleanor ^a   Hou, Liping ^a   Maher, Brion S ^b   Woldehawariat, Girma ^a   Kassem, Layla ^a   Akula, Nirmala ^a   Laje, Gonzalo ^a   McMahon, Francis J ^a  

^a NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

^b JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

African Americans; Ethnicity; Genetics; Pharmacology; SSRI

Indexed keywords

CITALOPRAM;

ADULT; ANXIETY; ARTICLE; CAUCASIAN; CONTROLLED STUDY; FEMALE; GENETICS; HUMAN; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; NEGRO; PRIORITY JOURNAL; RACE; RACE DIFFERENCE; SELF REPORT; SINGLE NUCLEOTIDE POLYMORPHISM; SOCIAL ASPECT; SOCIOECONOMICS; TREATMENT RESPONSE;

ADULT; AFRICAN CONTINENTAL ANCESTRY GROUP; ANTIDEPRESSIVE AGENTS; DEPRESSIVE DISORDER, MAJOR; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; GENETIC TESTING; GENOME-WIDE ASSOCIATION STUDY; HUMANS; MALE; MIDDLE AGED; MODELS, BIOLOGICAL; POLYMORPHISM, SINGLE NUCLEOTIDE; PSYCHIATRIC STATUS RATING SCALES; QUESTIONNAIRES;

EID: 84888007003     PISSN: 0893133X     EISSN: 1740634X     Source Type: Journal    
DOI: 10.1038/npp.2013.166     Document Type: Article

References (44)

1. Altshuler DM, Gibbs RA, Peltonen L, Dermitzakis E, Schaffner SF, Yu F et al (2010). Integrating common and rare genetic variation in diverse human populations. Nature 467: 52-58.
2. Baldwin DS, Lopes ATV (2009). The influence of comorbid anxiety disorders on outcome in major depressive disorder. Medico-graphia 31: 126-130.
3. Brown C, Schulberg HC, Madonia MJ, Shear MK, Houck PR (1996). Treatment outcomes for primary care patients with major depression and lifetime anxiety disorders. Am J Psychiatry 153: 1293-1300.
4. Costello AB, Osborne JW (2005). Best practices in exploratory factor analysis: recommendations for getting the most from your analysis. Practical Assessment Res Eval 10: 1-9.
5. Cultler JA, Rush AJ, McMahon FJ, Laje G (2012). Common genetic variation in the indoleamine-2, 3-dioxigenase genes and anti-dpressant treatment outcome in major depressive disorder. J Psychopharmacol 26: 360-367.
6. Fabrega H, Mezzich J, Ulrich RF (1988). Black-white differences in psychopathology in an urban psychiatric population. Compr Psychiatry 29: 285-297.
7. Garriock H, Kraft J, Shyn SI, Peters EJ, Yokoyama JS, Jenkins GD et al (2010). A genomewide association study of citalopram response in major depressive disorder. Biol Psychiatry 67: 133-138.
8. Gravlee CC, Non AL, Mulligan CJ (2009). Genetic ancestry, social classification, and racial inequalities in blood pressure in Southeastern Puerto Rico. PloS ONE 4: 1-9.
9. Henry BW, Overall JE, Markette JR (1971). Comparison of major drug therapies for alleviation of anxiety and depression. Dis Nerv Syst 32: 655-667.
10. Hooper D, Coughlan J, Mullen MR (2008). Structural equation modelling: guidelines for determining model fit. Electronic J Business Res Methods 6: 53-60.
11. Illi A, Setala-Soikkeli E, Viikki M, Poutanen O, Huhtala H, Mononen N et al (2009). 5-HTR1A, 5-HTR2A, 5-HTR6A, TPH1 and TPH2 polymorphisms and major depression. Neuroreport 20: 1125-1128.
12. Kang RH, Choi MJ, Paik JW, Hahn SW, Lee MS (2007). Effect of serotonin receptor 2A gene polymorphism on mirtazapine response in major depression. Int J Psychiatry Med 37: 315-329.
13. Keers R, Aitchison KJ (2011). Pharmacogenetics of antidepressant response. Expert Rev Neurother 11: 101-125.
14. Kishi T, Yoshimura R, Kitajima T, Okochi T, Okumura T, Tsunoka T et al (2009). HT2RA is associated with SSRI response in major depressive disorder in a Japanese cohort. Neuro-molecular Med 12: 237-242.
15. Laje G, Cannon DM, Allen AS, Klaver JM, Peck SA, Liu X et al (2010). Genetic variation in HTR2A influences serotonin transporter binding potential as measured using PET and [11C]DASB. Int J Neuropsychopharmacol 13: 715-724.
16. Laje G, Paddock S, Manji H, Rush AJ, Wilson AF, Charney D et al (2007). Genetic markers of suicidal ideation emerging during citalopram treatment of major depression. Am J Psychiatry 164: 1530-1538.
17. Laje G, Perlis RH, Rush AJ, McMahon FJ (2009). Pharmacogenetics studies in STAR*D: strengths, limitations, and results. Psychiatr Serv 60: 1446-1457.
18. Lee SJ (2009). Defining statistical race and phenotypic race and their implications for health disparities. Current Pharmaco-genomics Personalized Med 7: 238-242.
19. Lesser IM, Castro DB, Gaynes BN, Gonzalez J, Rush AJ, Alpert JE et al (2007). Ethnicity/Race and outcome in the treatment of depression. Results From STAR*D. Med Care 45: 1043-1051.
20. Lesser IM, Myers HF, Lin KM, Bingham Mira C, Joseph NT, Olmos NT et al (2010). Ethnic differences in antidepressant response: a prospective multi-site clinical trial. Depress Anxiety 27: 56-62.
21. Lesser IM, Zisook S, Gaynes BN, Wisniewski SR, Luther JF, Fava M et al (2011). Effects of race and ethnicity on depression treatment outcomes: the COMED trial. Psychiatr Serv 62: 1167-1179.
22. Lotrich FE, Pollock BG, Ferrell RE (2003). Serotonin transporter promoter polymorphism in African Americans: allele frequencies and implications for treatment. Am J Pharmacogenomics 3: 145-147.
23. Lucae S, Ising M, Horstmann S, Baune BT, Arolt V, Müller-Myhsok B et al (2010). HT2RA gene variation is involved in antidepres-sant response. Eur Neuropsychopharmacol 20: 65-68.
24. Luo HR, Poland RE, Lin KM, Wan YJ (2006). Genetic polymorphism of cytochrome P450 2C19 in Mexican Americans: a cross-ethnic comparative study. Clin Pharmacol Ther 80: 33-40.
25. McMahon FJ, Buervenich S, Charney D, Lipsky R, Rush AJ, Wilson AF et al (2006). Variation in the gene encoding the serotonin 2A receptor as associated with outcome of antidepressant treatment. Am J Hum Genet 78: 804-814.
26. Murphy EJ, Kassem L, Chemerinski A, Rush AJ, Laje G, McMahon FJ (2013). Retention and attrition among African Americans in the STAR*D Study: what causes research volunteers to stay or stray? Depression and Anxiety (in press).
27. Perlis RH (2007). Pharmacogenetic studies of antidepressant response: how far from the clinic? Psychiatr Clin N Am 30: 125-138.
28. Price ALP, Patterson NJ, Plenge RM, Weinblatt ME, Shadick NA, Reich D (2006). Principal components analysis corrects for stratification in genome-wide association studies. Nat Genet 38: 904-909.
29. Pritchard JK, Stephens M, Donelly P (2000). Inference of population structure using multilocus genotype data. Genetics 155: 945-959.
30. Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira MA, Bender D et al (2007). PLINK: a toolset for whole-genome association and population-based linkage analysis. Am J Hum Genet 81: 559-575.
31. Raskin A, Crook TH (1975). Antidepressants in Black and White inpatients. Differential response to a controlled trial of chlorpo-mazine and imipramine. Arch Gen Psychiatry 32: 643-649.
32. Ruhe HG, Ooteman W, Booij J, Michel MC, Moeton M, Baas F et al (2009). Serotonin transporter gene promoter polymorphisms modify the association between paroxetine serotonin transporter occupancy and clinical response in major depressive disorder. Pharmacogenet Genomics 19: 67-76.
33. Rush AJ, Fava M, Wisniewski SR, Lavori PW, Trivedi MH, Sackeim HA et al (2004). Sequenced treatment alternatives to relieve depression (STAR*D): rationale and design. Control Clin Trials 25: 119-142.
34. Simon J, Fleiss JE, Gurland BJ, Stiller PR, Sharpe L (1973). Depression and schizophrenia in hospitalized black and white mental patients. Arch Gen Psychiatry 28: 509-512.
35. Strickland TL, Ranganath V, Lin KM, Poland RE, Mendoza R, Smith MW (1991). Pharmacologic considerations in the treatment of black American populations. Psychopharmacol Bull 27: 441-448.
36. Strickland TL, Stein R, Lin KM, Risby E, Fong R (1997). The pharmacologic treatment of depression and anxiety in African Americans. Considerations for the general practioner. Arch Fam Med 6: 371-375.
37. Sucheston LE, Bensen JT, Xu Z, Singh PK, Preus L, Mohler JL et al (2012). Genetic ancestry, self-reported race and ethnicity in African Americans and European Americans in the PCaP Cohort. PloS ONE 7: e30950.
38. Tomarken AJ, Waller NG (2005). Structural equation modeling: Strengths, limitations and misconceptions. Annu Rev Clin Psychol 1: 31-65.
39. Trivedi MH, Rush AJ, Wisniewski SR, Nierenberg AA, Warden D, Ritz L et al (2006). Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: Implications for clinical practice. Am J Psychiatry 163: 28-40.
40. Uhlenhuth E, Paykel ES (1973). Symptom configuration and life events. Arch Gen Psychiatry 28: 747-748.
41. Warden D, Rush AJ, Wisniewski SR, Lesser IM, Thase ME, Balasubramani GK et al (2009). Income and attrition in the treatment of depression: a STAR*D report. Depression Anxiety 26: 622-633.
42. Warden D, Trivedi MH, Wisniewski SR, Davis L, Nierenberg AA, Gaynes BN et al (2007). Predictors of attrition during initial treatment for depression: A Star*D report. Am J Psychiatry 164: 1189-1197.
43. Wassel CL, Jacobs DR, Duprez DA, Bluemke DA, Sibley CT, Criqui MH et al (2011). Association of self-reported race/ethnicity and genetic ancestry with arterial elasticity: The Multi-Ethnic Study of Atherosclerosis (MESA). J Am Soc Hypertens 5: 463-472.
44. Yaeger R, Avila-Bront A, Abdul K, Nolan PC, Grann VR, Birchette MG et al (2008). Comparing genetic ancestry and self-described race in African Americans born in the United States and in Africa. Cancer Epidemiol Biomarkers Prev 17: 1329-1338.